Intelligent Bio Solutions Inc. Deploys First Shipment Of Intelligent Fingerprinting Drug Screening Readers Made Through New Partnership With Syrma Johari MedTech Ltd.

Intelligent Bio Solutions Inc., a medical technology company focused on intelligent, rapid, and non-invasive testing solutions, announced the successful receipt and deployment of the first shipment of its Intelligent Fingerprinting Drug Screening Readers manufactured through its new strategic partnership with Syrma Johari MedTech Ltd.. This shipment represents an important step in expanding the company’s production capacity and reinforces the operational and financial advantages outlined when the partnership was introduced in December 2025.

The newly manufactured readers are now being rolled out across major customer segments including construction, transportation and logistics, and manufacturing throughout the U.K. and Europe. This deployment supports increasing commercial demand while strengthening the company’s installed base ahead of its planned expansion into the U.S. market later this year, beyond the Forensic Use Only classification.

The successful delivery confirms that the collaboration with Syrma Johari is progressing as expected. All readers have met the company’s quality standards and were manufactured in line with ISO 13485, MDSAP, and all applicable regulatory requirements. With access to manufacturing capacity nearly four times higher than before, the company is now positioned to accelerate order fulfillment. It also expects to achieve more than 40% in annual production cost savings, which should translate into an improvement of roughly 20 percentage points in gross margin on a yearly basis.

Along with increasing reader production capacity, the company has also strengthened its in-house manufacturing capabilities for the lateral flow test strips used in its drug-screening system. The acquisition of advanced lateral flow manufacturing equipment has doubled its internal output, resulting in several strategic benefits. These include greater control over essential components that improve margins and reduce lead times, higher cartridge production that gives the product development team more inventory for rapid testing and innovation, and the flexibility to add additional test lines that enable the creation of expanded drug panels tailored to various customer needs, regulatory markets, or emerging substance trends.

Callistus Sequeira, Vice President of Global Quality and Operations at the company, stated that receiving and deploying the first shipment of readers from Syrma Johari along with the expanded test strip manufacturing capability, marks a transformational moment for the organization. He explained that the company is building a vertically integrated and cost-efficient manufacturing model designed to support stronger margins, faster innovation cycles, and a more robust operational foundation as it prepares for U.S. market entry. The company expects additional shipments throughout 2026 as it continues to build inventory, broaden its commercial reach, and execute on its regulatory and go-to-market plans for the United States.